PB 165 of 2025
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 5) 2025
I, Rebecca Richardson, as delegate of the Minister for Health, Disability and Ageing, make the following Determination.
Dated 18 December 2025
Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
Contents
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments—Additional designated brands effective from 1 June 2026
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Name
(1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 5) 2025.
(2) This instrument may also be cited as PB 165 of 2025.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | The day after this instrument is registered. |
|
3. Schedule 1 | 1 June 2026. | 1 June 2026 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments—Additional designated brands effective from 1 June 2026
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Section 5 (after table item dealing with the brand Estalis continuous 50/140 of the drug Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8)
Insert:
Repatha | Evolocumab | Injection 140 mg in 1 mL single use pre-filled pen | Injection |